CFTR and cystic fibrosis: We assessed the efficacy and safety of vanzacaftor–tezacaftor–deutivacaftor, a novel, once-daily CFTR modulator, compared with elexacaftor–tezacaftor–ivacaftor (standard of care for eligible people with cystic fibrosis) in 971 adolescents and adults with cystic fibrosis with diverse genotypes.